Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04512781 · ClinicalTrials.gov registry record · NA
Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Cannulae Designs
A NA study of Dyspnea and Respiratory Insufficiency, sponsored by Vapotherm.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT04512781: Completed NA study of Dyspnea and Respiratory Insufficiency, sponsored by Vapotherm.
NCT04512781 is a NA study of Dyspnea and Respiratory Insufficiency that has completed, run by Vapotherm. The registered enrollment target is 26 participants, below the 304-participant average among 23 other Dyspnea trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04512781, a NA study of Dyspnea and Respiratory Insufficiency, has completed, sponsored by Vapotherm.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate the ability of High Velocity Nasal Insufflation \[HVNI\] next generation nasal cannula designs to effect ventilation and related physiological responses relative to the conventional legacy cannula design.
Primary Outcome
Patient's subjective assessment of their dyspnea, rated as a modified Borg score on a scale from 0 to 10. Higher scores indicate a worse outcome.
Conditions Studied
Interventions
- DEVICE Control Cannula - Prosoft Cannula - Unicorn Cannula
- DEVICE Control Cannula - Unicorn Cannula - Prosoft Cannula
Study Locations (2)
Pennsylvania
- VA Pittsburgh Healthcare System - Pittsburgh
Tennessee
- Erlanger Baroness Hospital - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2022-06-07 |
| Phase | NA |
What the finished NCT04512781 record still lists
NCT04512781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 304-participant average among 23 other Dyspnea trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Dyspnea appearing as the primary indexed condition, and to 2 interventions - of which Control Cannula - Prosoft Cannula - Unicorn Cannula is the first listed.
NCT04512781 reports a single indexed study location in Pennsylvania, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04512781 about?
NCT04512781 is a clinical study titled "Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Cannulae Designs". This study will evaluate the ability of High Velocity Nasal Insufflation \[HVNI\] next generation nasal cannula designs to effect ventilation and related physiological responses relative to the conventional legacy cannula design.
What is the current status of trial NCT04512781?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2020-10-01. Estimated completion is 2022-06-07.
What conditions does trial NCT04512781 study?
This clinical trial studies the following conditions: Dyspnea, Respiratory Insufficiency, Hypercapnia.
What interventions are being tested in trial NCT04512781?
The interventions under investigation include: Control Cannula - Prosoft Cannula - Unicorn Cannula (DEVICE), Control Cannula - Unicorn Cannula - Prosoft Cannula (DEVICE).
Who is sponsoring clinical trial NCT04512781?
This trial is sponsored by Vapotherm, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04512781 being conducted?
This trial has 2 study locations across Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyspnea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04512781's enrollment target sits among peer trials
26 19th of 23 higher than 5 of 23 other Dyspnea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyspnea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)
RECRUITING · NA
-
Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy
RECRUITING · NA
-
Breathlessness Relieved by Employing Medical Air to be Titrated by Hospitalized Patients to Improve Inpatient Experience
ACTIVE NOT RECRUITING · NA
-
Improving Management of Breathlessness in Patients With Lung Cancer
COMPLETED · NA
-
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
COMPLETED · NA
-
Evaluation of Breathing Pattern and Dyspnea in Subjects With Tetraplegia
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI